Pulsenmore Ltd. · TASE:PLSM
Pulsenmore — Investor Presentation (March 2026)
24 slides from Pulsenmore's investor presentation, March 2026
Slide 1: Transforming Maternal Health Through Home Ultrasound
Transforming Maternal Health Through Home Ultrasound NASDAQ and TASE: PLSM
Slide 2: Legal Disclaimer- Forward Looking Statements
Legal Disclaimer- Forward Looking Statements This presentation contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “g
Slide 3: First and Only FDA-cleared Home-use Maternal Ultrasound System
Pulsenmore Developed the First and Only FDA-cleared Home-use Maternal Ultrasound System 3
Slide 4: The Pulsenmore Platform Technology
The Pulsenmore Platform Technology Patient self-scan device Mobile App Clinician Dashboard Connects with smartphone to Delivers personalized, step-by- Physicians prescribe and capture and securely transmit step scanning instructions review scans remotely, ultrasound images from home directly provide
Slide 5: Pulsenmore at a Glance
Pulsenmore at a Glance NASDAQ and TASE: Global leader in self- Strong patent portfolio; PLSM; Founded in scan home ultrasound Multi-center clinical 2014 validation Global Leader Regulatory Milestones Product Pipeline Financial Strength 220,000+ successful First FDA De Novo clearance Nov 2nd product
Slide 6: The Opportunity: Decentralized Prenatal Monitoring
The Opportunity: Decentralized Prenatal Monitoring Digital Health Cost-Efficient Transformation Models Total Addressable Market Remote monitoring Payers shifting toward adoption accelerating across healthcare Provider Shortages decentralized care delivery Consumer Demand 140M pregnancies globally OB
Slide 7: Access to Care in the U.S. is Unequal and Costly
Access to Care in the U.S. is Unequal and Costly Linternity Care Access Maternity Care Deserts (1918) Low Access to Care (273) 3.6M Moderate Access to care (223) Access to Matemity Care (2427) The Growing Gap Annual U.S. Deliveries A meaningful share of pregnancies require 35% of U.S. counties are R
Slide 8: Healthcare Challenges Today
Healthcare Challenges Today Growing Advanced maternal age and high- Capacity Clinics face space and staffing constraints, risk pregnancies increase prenatal with wait times averaging ~42 days, Demand Strain affecting care quality. care frequency. Rural and ethnic minority women face Costly ED ~750,0
Slide 9: U.S. Business Model
U.S. Business Model Device Sales 60% At-scale model: Single pregnancy use devices (~$1,000) for Device margin + high-margin SaaS/monitoring revenue high-risk pregnancies (~20% of births) + expansion to broader prenatal segments. Recurring SaaS Revenue 40% Device Margin High-margin SaaS Monitoring Pr
Slide 10: Our Competitive Advantages
Our Competitive Advantages FDA-Cleared Innovation with Clear Road map Products Value for Patients, Providers and One core platform, expandable to Payers new modalities, including IVF (already approved in Israel) and CHF The first and only FDA-cleared home-use (in development). prenatal ultrasound sy
Slide 11: Scalable Manufacturing
Scalable Manufacturing Pulsenmore developed the Long-term competitive advantage first & only fully automated production lines for Full manufacturing independence manufacturing ultrasound transducers Flexibility to meet changing demand Reduced raw material costs Superior quality and reliability Lower
Slide 12: Clinical Studies & Real-World Evidence
Clinical Studies & Real-World 98.1% Of Scans suitable for clinical Clinical Benefits Evidence evaluation Two RCTs (N=100) show reduced anxiety Reduced in-clinic visits and hospital admissions 220K+ Early detection and intervention Remote Scans 90% Of Users (Callit survey) report reduction in Perform
Slide 13: Strong endorsement from clinicians and patients
Strong endorsement At 39 weeks, Doria performed a home ultrasound scan. After from clinicians and reviewing the images, Professor Hadar advised her to come to the patients hospital immediately. Within 30 minutes of arrival, she gave birth - there wasn’t even time for an epidural. Doria Marley Prof.
Slide 14: Strategic Partnerships & Investments
Strategic 2016 Fujifilm Investment Strategic partnership established Partnerships & Investments 2020 Initial Clalit Agreement Multi-million-dollar contract with Israel's largest HMO 2021 TASE IPO Strategic partnership established 2022 GE HealthCare Major $21M strategic investment 2025 Phase 2 Clalit
Slide 15: Go-to-Market Strategy
Go-to-Market Strategy U.S. Commercial Launch '26 Europe & APAC • OB networks and hospitals • Expansion via leading institutions (UK, • Telehealth provider partnerships France, Australia) • Employer partnerships cost savings for patients • Large OB clinic partnerships • CPT 76815 available at launch
Slide 16: Board of Directors
Board of Directors Dr. Elazar Sonnenschein - CEO & Founder Mr. Jonathan Adereth - Chairman of the board Led several medical device and technology companies (NASDAQ: Veteran executive (NYSE: ELT, NASDAQ: MZOR), with 27 years at MDGS). PhD in Electronics & Computer Engineering, Ben-Gurion Elscint as P
Slide 17: New Product in the pipeline-Follicles monitoring
New Product in the pipeline-Follicles monitoring ✓ IVF and fertility preservation require 4–7 ultrasound scans per cycle, creating significant clinic load and patient burden. ✓ Home-based follicular monitoring unlocks scalable capacity and improves patient experience. AMAR authorization in Israel se
Slide 18: Growth & Strategy Outlook
Growth & Strategy Outlook 01 02 03 04 U.S. International R&D Pipeline Manufacturing Commercialization '26 Expansion Automation EU and global market Expanded indications to Industry-leading cost basis Launch penetration new modalities , AI and independent production diagnostics, enhanced visualizatio
Slide 19: Financial Highlights
FINANCIAL , HIGHLIGHTS ,
Slide 20: P&L 2025 vs. 2024
P&L 2025 vs. 2024 20 USD ‘000 METRIC Total revenue Gross profit Gross margin Operational loss Net Loss Before Income Tax Net Loss DEC 31, 2025 12,547 10,559 84% 3,814 4,970 4,970 DEC 31, 2024 2,649 981 37% 11,575 10,088 10,073 CHANGE +9,898 +9,578 +47pp -7,761 -5,118 -5,103 % +374% +976% -67% -51% -
Slide 21: Key Financial Highlights - 2025 vs 2024
Key Financial Highlights - 2025 vs 2024 GE Precision Gross profit Operating loss Net loss Healthcare improved by 10x, improved by improved by settlement from $0.98M to 67%, from $11.6M 51%, from $10.1M revenue: $9.57M $10.56M to $3.8M to $5M (one-time item) $21.7M in liquid Achieved a 21% Robust liq
Slide 22: Balance Sheet - 2025 vs. 2024
Balance Sheet - 2025 vs. 2024 22
Slide 23: Revenue and GP 2023-2025
Revenue and GP 2023-2025 $12,547 (in thousands) Revenue GE / Revenue recognition Gross profit $7,333 * 9.6M $2,241 $2,973 $2,649 84% $1,678 36% 37% 2023 2024 2025 * Including one-time GEHC settlement revenue: In 2025, the company recognized $9.6M in one-time revenue from a settlement agreement : In
Slide 24: Thank you.
ull Pulsenmore’ Home Ultrasoun Thank you.